Сборник содержит материалы научной мультиконференции «Биотех- нология медицине будущего»

СИМПОЗИУМ
«БАКТЕРИОФАГИ. УПРАВЛЕНИЕ МИКРОБИОТОЙ»

---

Всероссийская мультиконференция с международным участием «Биотехнология – медицине будущего»
29 июня - 2 июля 2019 г., г. Новосибирск, Россия
96
Immune response to phage and phage-derived products and its effects
on phage pharmacokinetics
Krystyna Dąbrowska
Institute of Immunology and Experimental Therapy, polish Academy of Sciences, Wrocław, 
poland
Use of viruses infecting bacteria (bacteriophages or phages) to treat bacterial infections has 
been ongoing clinically for approximately one hundred years. Despite that long history, along 
with a growing crisis of resistance to standard antibiotics, phage therapy is not yet a mainstream 
approach in medicine. One of important issues for phage therapy is phage pharmacokinetics, 
considered, from the practical point of view, as the difficulties that phages as virions can have in 
traveling through body compartments toward reaching target bacteria. Traditionally, pharma-
cokinetics is differentiated into four categories: these are absorption, distribution, metabolism, 
and excretion. Thus, pharmacokinetics in general comprise drug movement into and within 
body, along with drug clearance. Immune response to phage is a key factor that shapes phage 
clearance and thus it importantly contributes to phage pharmacokinetics together with phage 
ability to enter a system by various administration routes. In spite of the extraordinary diversity 
of bacteriophages and possible phage applications, phage morphology, phage specificity, phage 
dose, presence of sensitive bacteria or the characteristics of treated individuals (age, taxonomy) 
is related to phage bioavailability in animals and humans. However, once phages successfully 
enter the body, they reach most organs, including the central nervous system. Bacteriophages 
are cleared mainly by the immune system: innate immunity removes phages even when no 
specific response to bacteriophages has yet developed. Greater awareness of what obstacles 
related to pharmacokinetics generally or specifically can exist to phage therapy success, should 
aid in the further development of phage therapy toward wider use.

---

Всероссийская мультиконференция с международным участием «Биотехнология – медицине будущего»
29 июня - 2 июля 2019 г., г. Новосибирск, Россия
97